Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5

Journal of Endocrinology

Volumn 205, Issue 1, 2010, Pages 97-106

  Caton, Paul W ^a   Nayuni, Nanda K ^a   Kieswich, Julius ^a   Khan, Noorafza Q ^a   Yaqoob, Muhammed M ^a   Corder, Roger ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HISTONE ACETYLTRANSFERASE GCN5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MESSENGER RNA; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN; SIRTUIN 1; TRANSCRIPTION COACTIVATOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GENE; GENE ACTIVATION; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; LIVER; LIVER LEVEL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN INDUCTION; RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GLUCONEOGENESIS; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; METFORMIN; MICE; MICE, MUTANT STRAINS; P300-CBP TRANSCRIPTION FACTORS; PROTEIN KINASES; SIRTUIN 1; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 77949493599     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0345     Document Type: Article

References (46)

1. + metabolism and SIRT1 activity. Nature 458 1056-1060.
2. Caton PW, Nayuni NK, Murch O & Corder R 2009 Endotoxin induced hyperlactatemia and hypoglycemia is linked to decreased mitochondrial phosphoenolpyruvate carboxykinase. Life Sciences 84 738-744.
3. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, Yates J III & Montminy M 2007 Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449 366-369.
4. Dentin R, Hedrick S, Xie J, Yates J III & Montminy M 2008 Hepatic glucose sensing via the CREB coactivator CRTC2. Science 319 1402-1405.
5. Douthwaite JA, Lees DM & Corder R 2003 A role for increased mRNA stability in the induction of endothelin-1 synthesis by lipopolysaccharide. Biochemical Pharmacology 66 589-594.
6. Erion DM, Yonemitsu S, Nie Y, Nagai Y, Gillum MP, Hsiao JJ, Iwasaki T, Stark R, Weismann D, Yu XX et al. 2009 SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. PNAS 106 11288-11293.
7. Ford J, Ahmed S, Allison S, Jiang M & Milner J 2008 JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle 7 3091-3097.
8. Frescas D, Valenti L & Accili D 2005 Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. Journal of Biological Chemistry 280 20589-20595.
9. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurneyMW, Sauve AA & Sartorelli V 2008 Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Developmental Cell 14 661-673.
10. Gomez-Valades AG, Vidal-Alabro A,Molas M, Boada J, Bermudez J, Bartrons R & Perales JC 2006 Overcoming diabetes-induced hyperglycemia through inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP) with RNAi. Molecular Therapy 13 401-410.
11. Gomez-Valades AG, Mendez-Lucas A, Vidal-Alabro A, Blasco FX, Chillon M, Bartrons R, Bermudez J & Perales JC 2008 Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/dbmice. Diabetes 57 2199-2210.
12. Hardie DG 2008 Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Letters 582 81-89.
13. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, Radovick S & Wondisford FE 2009 Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137 635-646.
14. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ et al. 2008 SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. Journal of Biological Chemistry 283 20015-20026.
15. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR et al. 2000 Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49 2063-2069.
16. Ishdorj G, Graham BA, Hu X, Chen J, Johnston JB, Fang X & Gibson SB 2008 Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. Journal of Biological Chemistry 283 16818-16829.
17. Kain KH, Popov VL & Herzog NK 2000 Alterations in mitochondria and mtTFA in response to LPS-induced differentiation of B-cells. Biochimica et Biophysica Acta 1494 91-103.
18. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK et al. 2008 Metformin inhibits hepatic gluconeogenesis through AMP-dependent protein kinase-dependent regulation of orphan nuclear receptor SHP. Diabetes 57 306-314.
19. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P et al. 2005 The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437 1109-1111.
20. Lan F, Cacicedo JM, Ruderman N & Ido Y 2008 SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. Journal of Biological Chemistry 283 27628-27635.
21. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L & Sternglanz R 2000 The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. PNAS 97 5807-5811.
22. Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A & Puigserver P 2006 GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1a. Cell Metabolism 3 429-438.
23. Liu Y, Dentin R, Chen D, Hedrick S, Ravnskjaer K, Schenk S, Milne J, Meyers DJ, Cole P, Yates J III et al. 2008 A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456 269-273.
24. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB et al. 2007 Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450 712-716.
25. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J & Gerich J 1992 Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. New England Journal of Medicine 326 22-29.
26. Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Meneur C, Permutt MA & Imai S 2005 Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metabolism 2 105-117.
27. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E et al. 2005 Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. Journal of Medicinal Chemistry 48 8045-8054.
28. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL & Gao Q 2009 STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nature Cell Biology 11 492-500.
29. Owen MR, Doran E & Halestrap AP 2000 Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal 348 607-614.
30. Perriello G, Pampanelli S, Del Sindaco P, Lalli C, Ciofetta M, Volpi E, Santeusanio F, Brunetti P & Bolli GB 1997 Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM. Diabetes 46 1010-1016.
31. Puigserver P, Rhee J, Donovan J,Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D et al. 2003 Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1a interaction. Nature 423 550-555.
32. Rhee J, Inoue Y, Yoon JC, Puigserver P, Fan M, Gonzalez FJ & Spiegelman BM 2003 Regulation of hepatic fasting response by PPARgamma coactivator-1α (PGC-1): requirement for hepatocyte nuclear factor 4a in gluconeogenesis. PNAS 100 4012-4017.
33. Rodgers JT & Puigserver P 2007 Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. PNAS 104 12861-12866.
34. Rodgers JT, Lerin C, HaasW, Gygi SP, Spiegelman BM & Puigserver P 2005 Nutrient control of glucose homeostasis through a complex of PGC-1a and SIRT1. Nature 434 113-118.
35. Rodgers JT, Lerin C, Gerhart-Hines Z & Puigserver P 2008 Metabolic adaptations through the PGC-1a and SIRT1 pathways. FEBS Letters 582 46-53.
36. San KY, Bennett GN, Berrios-Rivera SJ, Vadali RV, Yang YT, Horton E, Rudolph FB, Sariyar B & Blackwood K 2002 Metabolic engineering through cofactor manipulation and its effects on metabolic flux redistribution in Escherichia coli. Metabolic Engineering 4 182-192.
37. Sasaki T, Maier B, Koclega KD, Chruszcz M, GlubaW, Stukenberg PT,Minor W & Scrable H 2008 Phosphorylation regulates SIRT1 function. PLoS ONE 3 e4020.
38. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M & Cantley LC 2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 1642-1646.
39. Sun Y, Liu S, Ferguson S, Wang L, Klepcyk P, Yun JS & Friedman JE 2002 Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. Journal of Biological Chemistry 277 23301-23307.
40. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B & Chung JH 2010 AMPK-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59 554-563.
41. Valera A, Pujol A, Pelegrin M & Bosch F 1994 Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulindependent diabetes mellitus. PNAS 91 9151-9154.
42. Veneziale CM, Donofrio JC & Nishimura H 1983 The concentration of P-enolpyruvate carboxykinase protein in murine tissues in diabetes of chemical and genetic origin. Journal of Biological Chemistry 258 14257-14262.
43. Wong AK, Howie J, Petrie JR & Lang CC 2009 AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clinical Science 116 607-620.
44. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK et al. 2001 Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 131-138.
45. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ & Cohen RA 2006 Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55 2180-2191.
46. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J,Wu M, Ventre J, Doebber T, Fujii N et al. 2001 Role of AMP-activated protein kinase in mechanismofmetformin action. Journal of Clinical Investigation 108 1167-1174.